Jones Day advises Catalent's Board of Directors in merger with Novo Holdings

Client(s) Board of Directors of Catalent Inc.

Jones Day advised the Board of Directors of Catalent, Inc. in the $16.5 billion merger of Catalent with Novo Holdings.

Novo Holdings acquired all the outstanding shares of Catalent for $63.50 per share in cash.

Catalent is no longer publicly traded on the New York Stock Exchange.

In connection with the transaction, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk (CPH: NOVO), in which Novo Holdings has a controlling interest. These three sites are located in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium.